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Abstract
Background and Objectives: In the last years, prepectoral breast reconstruction has
increased its popularity, becoming a standard reconstructive technique by preser-
ving pectoralis major anatomy and functionality. Nevertheless, the lack of solid and
extensive data negatively impacts on surgeons’ correct information about post-
operative complication rates and proper patient selection. This study aims to collect
the largest evidence on this procedure.
Methods: A multicentre retrospective audit, promoted by the Barcelona Hospital,
collected the experience of 30 centers on prepectoral breast reconstruction with
Braxon ADM. The study had the scientific support of INPECS and IIB societies which
provided the online database Clinapsis.
Results: A total of 1450 procedures were retrospectively collected in a 6‐year
period. Mean age 52.4 years, BMI 23.9, follow‐up 22.7 months. Reconstruction was
carried out after a tumor in 77.1% of the cases, 20.1% had prophylactic surgery,
2.8% had revisions. Diabetes, smoke, and immunosuppression had an influence on
complications occurrence, as well as implant weight. Capsular contracture was
associated with postoperative radiotherapy, but the overall rate was low (2.1%).
Complications led to implant loss in 6.5% of the cases.
Conclusions: The international Braxon Audit Group multicentre data collection
represents a milestone in the field of breast reconstruction, extensively improving
the knowledge of this procedure.
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1 | INTRODUCTION
Breast cancer nowadays represents the most common tumor among
women, with over 2 million new cases in 2018. Currently, its surgical
treatment is based on oncoplastic surgery, a synthesis between those
two disciplines with the final goal of an outcome balanced between the
best oncologic and cosmetic results. Indeed, since its conception, breast
reconstruction helped patients look “normal” when dressed; more re-
cently, advancements in surgical techniques and medical technologies
have raised the bar so that patients can feel esthetically pleasing also
unclothed.1 During the past decades, the surgical approach to breast
cancer has evolved from radical mastectomy to the development of
breast‐conserving surgery and reconstructive techniques. In fact, after
a nipple or skin‐sparing mastectomy, the opportunity of having per-
formed an immediate reconstruction represents a great advantage for
patients, owing to its significant psychosocial benefits. Currently, im-
mediate implant‐based breast reconstruction (IBR) represents 81.9% of
all breast reconstructive procedures.2
However, only in the last decade, surgeons approached the
prepectoral technique considering the importance of the role of the
pectoralis major muscle and the possibility to avoid its recruitment
for implant coverage: starting with the first cases described by Berna
et al, the subcutaneous breast implant positioning became a concrete
option, along with a complete breast implant wrapping with a large
sheet of ADM to prevent the direct contact of the silicone prosthesis
with the surrounding tissues.3,4
Prepectoral breast reconstruction (PPBR) has quickly become
more and more popular due to its satisfying esthetic outcomes, low
functional detriment, and low complication rate. In fact, whereas the
traditional submuscular reconstructive technique involves several
drawbacks, such as unpleasant esthetic results and postoperative
discomfort due to implant displacement, animation deformity, and
capsular contracture, PPBR has overcome most of them.5,6
Unfortunately, despite the current multiplicity of different devices
committed to PPBR, there is still a lack of high‐quality evidence to
support the safety of these newmaterials. In fact, most of the published
studies are limited to small single‐center experiences with no homo-
geneous outcomes.7‐9 As mentioned above, the first biologic membrane
able to completely cover a silicone implant to position it sub-
cutaneously was a 0.6mm‐thick preshaped porcine ADM (Braxon;
DECOmed Srl, Venice, Italy).3 To date, this device represents the most
widely used one for PPBR in European and UK breast centers and the
only ADM with a specific patented design that allows a standardized
wrapping technique, reducing the number of variables so that data can
be more easily compared among different centers.10 After a pre-
liminary multicentre study on 100 PPBR cases carried out with Braxon
ADM,11 the first author encouraged a larger EU‐UK database on PPBR
performed with the same device to obtain valuable evidence about
outcomes and risk factors potentially linked to postoperative compli-
cations: for this reason, the group of study was defined as international
Braxon Audit Group (iBAG). Our study wants to represent an extensive
and homogeneous retrospective multicentre data collection that sets
the basis for future randomized prospective studies.
2 | MATERIALS AND METHODS
2.1 | Study design and participants
At the beginning of 2018 the coordinating center, Santa Creu i Sant Pau
Hospital of Barcelona (Spain), promoted an international audit on PPBR
to collect and analyze homogeneous data with the aim of creating the
largest evidence on this procedure. This study had the scientific support
of Institut d'investigaciò Biomèdica Sant Pau (IIB) and Instituto Para la
Excelencia Clínica y Sanitaria (INPECS), created by the Ibero‐American
Cochrane Collaboration Association (ACCIb) which provided the online
database CLINAPSIS. The access to the database was protected by
single‐user login credentials; it collected all information recorded in an
anonymized format. Data were managed by the above‐mentioned in-
dependent organisms (IIB and INPECS) to avoid any bias.
The coordinating center of Barcelona invited to take part in the
study of all EU and UK plastic and breast units performing PPBR rou-
tinely and having performed more than 10 procedures with the Braxon
ADM (DECOmed Srl). This collagen membrane is the most used for
PPBR and the sole with a specific patented design that allows a stan-
dardized wrapping technique. The various options in ADM assembly
constitute a critical point in the analysis of the outcomes of the proce-
dure since the wrapping phase of the reconstructive technique is op-
erator sensitive. The use of different devices to cover the breast implant
could lead to inhomogeneous data collection due to the different ma-
terials and the nonstandardized implant covering procedure.
With the aim of obtaining uniform data, all the consecutive PPBR
carried out only with Braxon porcine ADM from November 2012 to
June 2018 were retrospectively analyzed. Patients’ inclusion criteria
to PPBR were defined according to each center practice; indeed,
some general guidelines were already published about patient's se-
lection for PPBR procedure and they include women with no history
of radiation, non‐ or ex‐smokers, a reasonable subcutaneous layer, a
well‐perfused skin flap, an estimated mastectomy weight of less than
500 g and tumors not invading skin or chest wall, as well as those
with inflammatory nature. Considering the retrospective nature of
this study, the authors do not set any exclusion criteria with the aim
to verify any association between patient characteristics and post-
operative complications. Thus, if some of the 30 centers involved in
the iBAG study enlarged the indication, therefore offering PPBR to
thin or obese women, as well as diabetics or smokers, data coming
from these cases were analyzed as well. The sole patients excluded
from the analysis were those with less than 3 months of follow‐up.
Data analyzed were patients’ age, body mass index (BMI), co-
morbidities, smoking status, tumor classification, neo‐adjuvant or
adjuvant chemotherapy, previous or adjuvant radiation therapy (RT),
previous breast surgery, uni‐ or bilateral procedures, type of surgery
(therapeutic, prophylactic or revision), type of mastectomy, breast
skin incision, type of implant used, implant volume, axillary surgery,
postoperative therapies, and complications. Complications were
classified in “immediate” or “late” whether if they occurred respec-
tively within or after 3 months from surgery. The complications ob-
served included seroma, wound dehiscence, hematoma, skin necrosis,
2 | MASIÀ ET AL.
infection, implant extrusion, implant rotation, capsular contracture,
rippling, and implant loss. Moreover, we collected all details about
pre‐ and postoperative medical treatments, hospitalization period,
and pre‐ and postoperative patients’ pictures.
2.2 | Ethical standards
The research protocol of the study was approved by the Ethics Com-
mittee of the Santa Creu i Sant Pau Hospital; each participating center
was required to obtain local committee approval. In accordance with
the Declaration of Helsinki of 1975, as revised in 1983, all patients
were asked to provide written consent for the use of their personal
data, as part of the standard surgical consent of their institutions. Pa-
tients’ data were visible only to the supervisors of each center where
the reconstructive procedure was carried out; no one else had access
to those records. At the end of the period of data collection, the co-
ordinating center had the authorization to manage all the anonymized
data and to analyze them through statistical protocols.
2.3 | Material and surgical procedure
After mastectomy or surgery performed for revision purposes, the
reconstructive phase involves the preparation of the ADM, which re-
quires rehydration of 5minutes in room‐temperature saline solution to
facilitate its handling. Then, the ADM is wrapped around the breast
implant, its excess is cut away and it is closed by mean of absorbable 3/
0 suture (Figure 1). Then, the completely wrapped implant is placed
inside the breast pocket and fixed with cardinal stitches to the pec-
toralis major muscle fascia and to the subcutaneous layer through
quilting sutures in the anterior part of the Braxon ADM, thus elim-
inating dead spaces and supporting ADM integration.
Surgeons involved in the study performed mastectomies according
to specific clinical scenarios and their routine practice with the only
common characteristic that the reconstructive phase did not entail the
pectoralis major; implant selection (round or anatomical shape, fixed‐
volume or adjustable implant, as well as temporary tissue expander)
depended on surgeons’ preference. Breast reconstruction was then
classified as two‐stage when performed with an expander or one‐stage
when a definitive implant was used. In some cases, the ADM was used
for patients requiring revision surgery due to implant‐related
complications or undesired surgical outcomes.
In all cases, perioperative and postoperative antibiotics and
drains were used according to local policy.
2.4 | Statistical analysis
Considering the relevant sample size, χ² and the Student t test tests
were firstly used to study all independent variables potentially influ-
encing the studied outcome, particularly postoperative complications. A
model was then designed for all variables to explain the evidence de-
rived from the data set; it was based on hierarchical and generalized
additive models (GAM), mainly dictated by the poor plausibility of a
linear link between regressors and the response variable, which need
to exploit the flexibility of the GAM models. Moreover, for each vari-
able there were differences between several sample units dictated by
some specific characteristics of the data collection, thus motivating the
use of hierarchical models. Variables with more than 20%of missing
data were excluded from the statistical analysis.
The adopted approach studies simple models first, with a single
explanatory variable. After verifying the ability of these variables into
the model description, they are included in a multiple logistic re-
gression model, thus increasing the improvement of the estimates
and the goodness of adaptation of the model to the data (Stepwise
Method). The level for statistical significance was set at P < .05. All
statistical analyses were performed with R version 3.5.1 (2018),
Rstudio Version 1.1.456, CRAN project.
3 | RESULTS
Thirty clinical centers, shared between Spain, UK, and Italy, took part in
the study. Data collection started in September 2018 and finished in
January 2019; preliminary data of the present study were presented at
Barcelona Breast Meeting (BBM) and at Oncoplastic and Reconstructive
Breast Surgery (ORBS) conference, both held in 2019.
The iBAG identified 1450 PPBR, carried out in 1186 women, in a
6‐year period comprised between November 2012 and June 2018.
Demographic, clinical, and surgical details of the patients are
explained in Table 1.
F IGURE 1 Standardized wrapping technique of Braxon ADM around the breast implant. The patented shaped allows a complete cover
acting as an internal “implant bag” which distributes the weight of the silicone prosthesis around all the breast pocket and hides it from the
direct contact with the organism. ADM acellular dermis matrix [Color figure can be viewed at wileyonlinelibrary.com]
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A t‐test analysis revealed a significant difference in hospitalization
time mean for patients with hypothyroidism (P‐value = .016), with pre-
operative chemotherapy (P‐value = .004), patients who underwent ax-
illary surgery (P‐value = .008), with postoperative chemotherapy (P‐
value = .003) or radiotherapy (P‐value = .018). All these patients were
more likely to have longer hospital stay; also, the type of reconstruction
(one‐ or two‐stage) influenced hospital stay (P‐value = .001).
Patients had a mean follow up period of 22.7 months (range
3‐75.7): they were postoperatively checked in each clinic following
standard practice and patients’ complications were recorded and
treated during follow up visits. Complications were analyzed con-
sidering the problem as breast‐related, not patient‐related, as each
breast has its own individual risk factors. For example, a patient who
underwent a bilateral mastectomy and PPBR may need radiation
therapy on one side and no therapy on the contralateral breast, this
way risk factors for postoperative complications would differ
between the breasts.







Follow‐up 22.7 ± 13.1 (3‐75.7)
Demographic/clinical
AGE 52.4 ± 11.4 (17‐87)
BMI 23.9 ± 4.1 (15.6‐40)
Comorbidities Obese 56 (4.7)
Diabetes 28 (2.4)






Smoking status Active smokers 120 (10.1)
Ex‐smokers 62 (5.2)
Use of drugs Immunosuppressants 7 (0.6)
Anticoagulants 26 (2.2)
















Multiples /mixed 77 (5.3)
Other 48 (3.3)
None 298 (20.6)
Chemotherapya Neoadjuvant 141 (11.9)
Adjuvant 216 (18.2)





Both treatments 3 (0.2)
Surgical (per breast)
Type of surgery Therapeutic 1118 (77.1)
Prophylactic 291 (20.1)
Revision 41 (2.8)
Axillary dissection 187 (12.9)














Mastectomy weight 369.7 ± 201.4
(42‐1200)
















Not defined 182 (12.6)
Expander 25 (1.7)
Incisions Inverted‐T 109 (7.5)
Round block 29 (2.0)





Not defined 77 (5.31)
Hospital stay, d 3.2 ± 2.7 (0.5‐21.0)
Abbreviations: iBAG, International Braxon Audit Group; DCIS, ductal
carcinoma in situi; IDC, invasive ductal carcinoma; ILC, invasive lobular
carcinoma; LCIS, lobular carcinoma in situ; NAC, nipple‐areolar complex;
RBS, red breast syndrome.
aNineteen patients had chemotherapy but missing data on
administration time.
bNine breasts had missing data about radiation treatments.
cTwenty seven procedures had missing data on implant profile.
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As shown in Table 2, a total of 200 breasts experienced immediate
complications while late complications occurred in 61 breasts; 46.7% of
the total complications had no records about their onset. Among all
PPBR, the implant loss rate was 6.5%, while 76.2% of all complicated
breasts were conservatively treated. Most of the implant losses occurred
in the early period (41 breasts; 2.8% vs 27 breasts; 1.9%); moreover,
immediate complications were mainly surgery‐related adverse events
such as seroma, wound dehiscence, hematoma, skin necrosis and infec-
tion. On the other side, late complications are mostly represented by
implant‐related problems, in particular, capsular contracture and rippling
(Table 2). In a considerable number of patients, the timing of adverse
events was not specified, so the complication timing was not included in
the statistical analysis, focusing it on the total complication number and
on the risk factors affecting their occurrence.
Among the breasts that developed complications, most showed the
incidence of a single adverse event (n = 284; 72.6%). In these cases, the
removal of the implant was carried out in 17.6% (n =50). Considering
breasts suffering from two complications (n = 66; 16.9%), implant loss
rate raise at 30.3% (n = 20), while breasts that reported three or more
complications (n = 37; 9.5%) led to implant loss in more than half of the
cases (n = 22; 59.5%). Two women had the removal of the breast implant
but no records on occurred complications were collected.
The multivariate analysis of the risk factors contributing to compli-
cation onset underlined an increased risk of seroma formation in patients
using immunosuppressive drugs (RR= 4.56; P‐value = .017) as well as
those who had had a previous esthetic breast surgery
(RR=2.54; P‐value = .030) or an axillary dissection during the PPBR
(RR=1.67; P‐value = .039); also the type of tumor seemed to increase
seroma onset (P‐value = .029).
Infection instead is more likely to occur in diabetics (RR = 4.026;
P‐value = .003) and ex/active smokers (P‐value = .016) with RR = 2.15
for ex‐smokers and 2.08 for active smokers. Axillary dissection also
influenced infection onset (RR = 2.17; P‐value = .009) and an in-
creasing implant volume showed, both in univariate and multivariate
analysis, a higher risk of infection development, with an infected
breast mean volume of 409.3 g compared to those of noninfected
cases of 346.2 g (P‐value = .001). Always regarding the infection oc-
currence, statistical significance was highlighted both by univariate
and multivariate analysis for the type of incision used (P‐value <.05)
except for the round‐block technique.
Considering risk factors for wound dehiscence, multivariate
analysis demonstrated a high impact of active smoking habits on this
complication (RR = 2.49; P‐value = .001). Moreover, skin reducing
mastectomy appeared to be more at risk of wound dehiscence
(RR = 5.19; P‐value = .047) compared to nipple‐sparing mastectomy;
also the type of surgical incision chosen (P‐value <.05), particularly
wise pattern, influenced wound dehiscence.
Smoking status, immunosuppressive drugs and implant volume
were risk factors involved in postoperative mastectomy flap necrosis
(P < .05); particularly, mean implant volume in complicated patients
was 406.8 g while for the other ones it was 347.3 g.
Active smokers and diabetics are prone to develop RBS
(respectively RR = 2.42, RR = 3.90; P‐value = .02); the presence of
a previous mastectomy has demonstrated a connection with RBS
as well (RR = 6.55; P‐value = .044). The univariate analysis also
gave significance to the implant volume variable (P‐value = .004)
although the multivariate did not confirm the value
(P‐value = .058).
























Seroma 111 (7.7) 103 (8.7) 52 (3.6) 47 (4.0) 3 (0.2) 3 (0.3) 56 (3.9) 53 (4.5)
Dehiscence 67 (4.6) 63 (5.3) 28 (1.9) 27 (2.3) 0 (0) 0 (0) 39 (2.7) 36 (3.0)
Hematoma 31 (2.1) 31 (2.6) 20 (1.4) 20 (1.7) 0 (0) 0 (0) 11 (0.8) 11 (0.9)
Necrosis 46 (3.2) 42 (3.5) 21 (1.4) 18 (1.5) 2 (0.1) 2 (0.2) 23 (1.6) 22 (1.9)
Infection 70 (4.8) 64 (5.4) 25 (1.7) 23 (1.9) 5 (0.3) 5 (0.4) 40 (2.8) 36 (3.0)
Extrusion 18 (1.2) 17 (1.4) 6 (0.4) 6 (0.5) 5 (0.3) 5 (0.4) 7 (0.5) 7 (0.6)
RBS 48 (3.3) 46 (3.9) 17 (1.2) 16 (1.3) 1 (0.1) 1 (0.1) 30 (2.1) 29 (2.4)
Fever 25 (1.7) 16 (1.3) 19 (1.3) 12 (1.0) 0 (0) 0 (0) 6 (0.4) 4 (0.3)
Implant rotation 3 (0.2) 3 (0.3) 0 (0) 0 (0) 3 (0.2) 3 (0.3) 0 (0) 0 (0)
Capsular contracture 31 (2.1) 26 (2.2) 5 (0.3) 4 (0.3) 17 (1.2) 14 (1.2) 9 (0.6) 8 (0.7)
Rippling 40 (2.8) 30 (2.5) 7 (0.5) 4 (0.3) 25 (1.7) 19 (1.6) 8 (0.5) 7 (0.6)
Other complications 48 (3.3) 46 (3.9) 11 (0.8) 9 (0.8) 6 (0.4) 6 (0.5) 31 (2.1) 31 (2.6)
Implant loss 94 (6.5) 89 (7.5) 41 (2.8) 37 (3.1) 27 (1.9) 25 (2.1) 26 (1.8) 26 (2.2)
Abbreviation: RBS, red breast syndrome.
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Capsular contracture was related to postoperative radiation ther-
apy (RR = 3.90; P‐value < .05) both in univariate and multivariate ana-
lysis; moreover, this complication seems to be more common in patients
having a PPBR for revision surgery (RR= 16.36; P‐value = .001) or
having had a previous breast augmentation (RR =5.02; P‐value = .009)
or breast reconstruction (RR =8.93; P‐value < .05).
Patients were further divided into two subgroups: those
undergone radiation therapies (pre‐ or postoperatively) and those
not irradiated, to evaluate with a univariate analysis the potential
impact of this treatment on postoperative complications (Table 3).
Through univariate analysis, it was investigated if radiation therapy,
administered pre‐ or postoperatively, could represent a significant
risk factor for complication development, comparing three groups of
patients undergone previous, postoperative or no radiation treat-
ment. Radiation therapy appeared to be a statistically significant risk
factor for the development of postoperative seroma, capsular con-
tracture, rippling, and implant loss, especially for patients undergone
postoperative RT administration. Interestingly, at multivariate ana-
lysis, the negative impact of RT was confirmed only on capsular
contracture, having no statistically significant association with the
occurrence of all other complications (Table 3).
Six patients are shown in Figures 2‐4 as representative examples of
PPBR esthetic outcomes. Each figure shows two cases with preoperative
and postoperative pictures in lateral and frontal views.
4 | DISCUSSION
Prepectoral ADM‐assisted breast reconstruction is growing in fame
among all European and American hospitals, with the aim of im-
proving patients’ esthetic and functional outcomes, such as their
quality of life.5,6 The advantages of PPBR compared to the tradi-
tional submuscular approach are well described in several publica-
tions, but lack of data from large cohorts of patients negatively
affects the quality of scientific information. Moreover, inadequate
information about the technique also affects the surgeon's judg-
ment for a correct patient selection, thus increasing the risk of
developing postoperative complications. The aim of this data col-
lection was to obtain the largest evidence on PPBR performed with
a complete Braxon ADM implant wrapping, to acquire unquestion-
able statement about PPBR outcomes and consequently lead to
correct patient selection.
This retrospective multicentre study collected 1450 cases, thus
defining the largest database of ADM‐assisted PPBR patients; compli-
cation rates were acceptable and always below 8%, with an overall
reconstruction failure of 6.5%. Statistical analysis showed a higher risk
of developing postoperative complications for active smokers, diabetics,
and patients who had had previous breast surgery or currently taking
immunosuppressants; additionally, some surgical details such as implant
volume, type of skin incision or mastectomy seem to affect complication
rate. The adverse effect of postoperative radiation therapy was con-
firmed only on capsular contracture occurrence (RR =3.90; P‐value
<.05) but always with a low overall rate, set around 2%.
The few publications about one‐step PPBR reported outcomes in
line with the data raising the iBAG study. Evidence about immediate
one‐step PPBR are mainly from European clinical experiences, most
of them performed with the use of Braxon ADM.3‐6,11‐13 From these
publications a similar rate of implant loss is observed, set around 4%;
an exception is represented by Vidya's multicentre study, which re-
ported 2% of failure rate on 100 cases; this series was characterized
by highly selected patients, with low associated risk factors, and this
could explain the low complication rate.11
The study by Reitsamer et al on 200 PPBR with implants wrapped
either with ADM or synthetic mesh showed the following complication
rate among the total reconstructed breasts in a 36‐months follow‐up:
7% of necrosis, 4% of hematoma, 14.5% of seroma, 2.5% of implant
rotation and 1.5% of rippling; lipofilling was required in 3.5% of the
women. Although complication rates in this study were quite higher
than those reported in the iBAG study, we are not able to associate
them specifically with one of the two materials used to cover the
implant, since the authors did not correlate outcomes with membrane
type.14 Instead, we are led to consider the surgical approach chosen as
the critical factor impacting outcomes, since 79.5% of cases underwent
mastectomy through inframammary fold incision versus 13% of iBAG
experience. In fact, this surgical access reduces breast pocket visibility,
thus increasing the risk of accidental damage to nipple vascular plexus,
thus explaining the higher rate of nipple‐areolar complex necrosis (7%
vs 3.2% of the iBAG cohort). Even seroma incidence is doubled in
Reitsamer's paper, when compared to 7% of the present study; this
could be explained with the presence of chemical preservatives
(Polysorbate 20) present in the ADM used, which may cause a higher
postoperative inflammatory reaction. An observation should be also
made on implant rotation rate, 12 times higher than that reported in
iBAG data, which may originate from the different wrapping techni-
que: in fact, Reitsamer's approach involves only a frontal implant
covering while iBAG study used an ADM able to create a whole
“pocket” which tightly fits the anatomical profile of the breast implant
and avoid implant rotation.
In Highton et al's15 and Chandarana et al's12 experiences, the
rate of necrosis was found to be slightly higher than iBAG collection,
as they reported respectively 4.4% and 5.2% rates. Even though the
ADM used was the same as iBAG study, immediate and late com-
plication rates of Chandarana's analysis were consistently higher
than ours (hematoma 6.9%, infection 6%, seroma 13.3%). In our
opinion, the differences in clinical and surgical details of the popu-
lations between the two studies might have played a role in adverse
events occurrence.
Overseas, studies have been published by American authors which
have performed PPBR on larger cohorts, yet in a two‐stage procedure
with the use of tissue expander covered with ADM positioned on the
frontal part only.16 Moreover, the use of porcine ADM is still un-
common among the main American scientific papers, so that most evi-
dence derives from human dermis such as AlloDerm.17 The analysis of
these studies should bring up concern on more aspects, the fact that
two‐stage techniques require a second surgery to exchange the device
with a definitive implant and the relative increased risk of tumor
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F IGURE 2 A‐C, Preoperative pictures in lateral and frontal view, slight asymmetry of the right breast due to a previous clinical investigation;
D‐F outcomes at 21 months of unilateral right nipple‐sparing mastectomy and prepectoral breast reconstruction with Braxon; G‐I, preoperative
lateral and frontal views of an IDC left case; J‐L, outcome of left immediate prepectoral reconstruction after nipple‐sparing mastectomy and
right breast augmentation, 7 months postop. IDC, invasive ductal carcinoma [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 3 A‐C, Preoperative lateral and frontal views; D‐F, 12 months postop outcomes of left immediate prepectoral breast
reconstruction; G‐I, frontal and lateral views of right IDC case; J‐L, 7 months from the bilateral prepectoral reconstruction after nipple‐sparing
mastectomies [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 4 A‐C, Preoperative lateral and frontal pictures of a right DCIS case; D‐F, esthetic result after 6 months of right immediate
prepectoral reconstruction; G‐I, preoperative lateral and frontal pictures of a failure of previous left breast reconstruction; J‐l, outcomes of left
delayed prepectoral breast reconstruction, 24 months postoperative. DCIS, ductal carcinoma in situ [Color figure can be viewed at
wileyonlinelibrary.com]
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recurrence.18 In European daily practice, a direct‐to‐implant single‐stage
PPBR is preferably offered, since in most women a second procedure
can be easily spared. Moreover, multiple surgeries are associated with
an increased infection risk which could find confirmation in higher in-
fection rates reported in the main American PPBR experiences.19 In
fact, Nahabedian reported very high infection rates (12.8% by patient;
8.1% by breast) not in line with iBAG study outcomes, while implant loss
rate was similar (6.5%) and slightly different necrosis and seroma rates
(9.7% and 4.8%).17 High implant and expander loss rate, as well as
infection one, were also found in Bettinger and Schnarrs publications
about prepectoral expander/implant reconstructions, with overall
infection rates of 9.1% for the first one and 11.8% for the second,
reinforcing again our hypothesis.20,21
Furthermore, patient's risk factors revealed by our statistical ana-
lysis find confirmations in other publications: Schnarrs highlighted
higher postoperative complications risk in smokers and patients with
>500 g breasts,20 while Bettinger observed increased complication rates
in previously irradiated breasts and no significant association between
chemotherapy and postoperative adverse events.21
In iBAG analysis a secondary interest was to investigate RT impact
on postoperative outcomes; the multivariate analysis did not reveal any
statistically significant correlation between RT and postoperative com-
plications, except for capsular contracture, that even so did not reach a
high percentage (about 2%) (Table 3). Very few publications until now
have focused their studies on PPBR and RT and moreover their popu-
lations were limited to small cohorts with a maximum of 54 patients
undergone unilateral RT.22‐24 Even in these series the authors had ex-
perienced only with the two‐stage reconstructive procedure and not with
a direct‐to‐implant (DTI) PPBR. With regard to the impact of radio-
therapy on PPBR outcomes, the iBAG study collected 190 irradiated
patients for a total of 198 DTI‐PPBR, which to our knowledge represent
the largest evidence on this issue. The outcomes resumed in Table 3
demonstrated, especially for postoperative RT, no association with the
onset of postoperative complications, except for capsular contracture.
The retrospective review by Elswick et al about irradiated PPBR
collected the largest number of patients published up to now but with
just 9 months of follow‐up; in this study, RT was found not to have any
statistical association with adverse event occurrence, despite the overall
higher rates of complications in the irradiated group vs the non-
irradiated one (25.9% vs 23.1%): infection rate was high in both groups
(18.5% vs 7.7%), as in most American publications on PPBR. Capsular
contracture rate was higher in the irradiated group (1.9% vs 0%), as we
observed in iBAG experience (5.1% vs 1.7%); the slightly different
percentage could be probably due to the different distribution of the
iBAG population, which was richer in smokers (7.9%), diabetics (1%) and
patients with hypothyroidism (7.1%), when compared to Elswick's
review, or due to the shorter follow‐up of this review.24
In the same year, the publication by Sinnott et al25 compared
irradiated and nonirradiated patients, stratified by prepectoral or
subpectoral procedure; the subpectoral reconstruction showed
overall higher capsular contracture rate than PPBR (9.8% vs 5.2%),
especially in irradiated breasts (52.2% vs 16.1%), confirming the
TABLE 3 Comparison of irradiated and nonirradiated breasts developing postoperative complicationsa
Complications
Nonirradiated
Nr = 1243 breasts Irradiated Nr = 198 breasts
b Preop RT Nr = 45 breastsc Postop RT Nr = 159 breasts
c
Nr (%) Nr (%) RR P‐value Nr (%) RR P‐value Nr (%) RR P‐value
Seroma 87 (7.0) 22 (11.1) 1.53 .042 5 (11.1) 1.52 .363 17 (10.7) 1.49 .100
Dehiscence 56 (4.5) 8 (4.0) 0.91 .768 1 (2.2) 0.49 .461 7 (4.4) 1.02 .951
Hematoma 27 (2.2) 4 (2.0) 0.97 .948 0 (0.0) 0.00 .320 4 (2.5) 1.23 .662
Necrosis 38 (3.1) 8 (4.0) 1.28 .465 2 (4.4) 1.41 .630 6 (3.8) 1.21 .632
Infection 59 (4.7) 10 (5.1) 1.06 .852 2 (4.4) 0.92 .910 8 (5.0) 1.09 .810
Extrusion 13 (1.0) 5 (2.5) 2.05 .082 3 (6.7) 5.63 <.05 2 (1.3) 1.08 .906
RBS 44 (3.5) 4 (2.0) 0.60 .268 0 (0.0) 0.00 .205 4 (2.5) 0.76 .565
Fever 24 (1.9) 1 (0.5) 0.29 .153 0 (0.0) 0.00 .364 1 (0.6) 0.36 .265
Implant rotation 3 (0.2) 0 (0.0) 0.00 .489 0 (0.0) 0.00 .755 0 (0.0) 0.71 .545
Capsular contracture 21 (1.7) 10 (5.1) 2.42 .002 0 (0.0) 0.00 .312 10 (6.3) 3.10 <.05
Rippling 39 (3.1) 1 (0.5) 0.18 .036 1 (2.2) 0.79 .817 0 (0.0) 0.00 .025
Other complications 39 (3.1) 9 (4.5) 1.38 .305 2 (4.4) 1.35 .675 7 (4.4) 1.36 .401
Implant Loss 70 (5.6) 22 (11.1) 1.83 .003 5 (13.3) 1.83 .189 17 (10.7) 1.80 .014
Note: 2. Nr. 6 breasts had data about preoperative treatment but no evidence about the postoperative therapy; Nr. 2 breasts had data about
postoperative radiation but no details about preoperative treatment.
Abbreviation: RBS, red breast syndrome.
aNr. 9 breasts had no data on radiation therapy.
bNr. 6 breasts had data about preoperative treatment but no evidences about the postoperative therapy; Nr. 2 breasts had data about postoperative
radiation but no details about preoperative treatment.
cNr. 3 breasts had both treatments, pre and postoperative.
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ability of ADM to prevent from capsular contracture and the effec-
tiveness of prepectoral implant positioning vs the submuscular one.
Prepectoral and submuscular breast reconstruction were also
evaluated by Sbitany and colleagues comparing irradiated and not‐
irradiated breasts from a single center experience; the two groups
undergoing postmastectomy RT revealed different complication
rates with overall higher rates in PPBR group. Infection represented
again the highest issue (42.4% in PPBR vs 32.2%), followed by ex-
plant rate (15.4% in PPBR vs 19.3%), wound dehiscence (15.4% in
PPBR vs 12.9%), skin necrosis (26.9%, in PPBR vs 9.7%), seroma and
hematoma (both 7.7%. in PPBR vs 3.2%). Despite the high incidence
of complications, no statistical evidence of influence between post-
mastectomy RT and PPBR outcomes were observed.26
The role of ADM in the prevention of periprosthetic fibrosis was
evaluated in several papers, also before the birth of PPBR, and its po-
sitive effect was confirmed in mutual agreement.27,28 Moreover, the
study by Onesti et al4 described the specific behavior of the ADM
Braxon confirming, through ultrasound and histologic examinations, the
formation of a new layer in the subcutaneous tissue that is less prone to
contract during the years. Nevertheless, in some recent publications on
PPBR, the ADM implant covering has been questioned again. The study
by Salibian et al29 proposed a staged subcutaneous reconstruction
without any expander cover, but it revealed 7.6% of capsular con-
tracture (Baker III and IV) in a series of 155 patients (250 breasts)
reconstructed with a “naked” prepectoral expander. The same doubt
about the need of ADM to cover the implant in PPBR was the basis of
the retrospective study by Singla et al30 from the analysis of the im-
mediate single‐stage subcutaneous reconstructions carried out without
any coverage of the silicone implant raised the following complications
rate: 15.3% of seroma, 15.3% of infections, 11.5% of implant rotation,
3.8% of capsular contracture and 19.2% of implant visibility and contour
defects; far from the results of iBAG data collection. These results lead
us to consider the complete ADM cover a crucial point in PPBR to
reduce the risk of periprosthetic fibrosis.
In conclusion, the iBAG data collection represents the largest
study on PPBR performed using a complete implant wrapping
through a preshaped porcine ADM. Data from this retrospective
multicentre audit confirm the effectiveness of the technique and the
low postoperative complication rate, especially capsular contracture;
moreover, an ideal patient profile has been drawn by assessing the
risk factors involved in postoperative complications’ onset.
The authors agree to consider this study limited by its retrospective
nature, especially for those patient's characteristics and intraoperative
details that were collected in a percentage too small to reach the value
sufficient for the statistical analysis and which in the future should be
further investigated to better describe the correct patient selection. For
this reason, a prospective study is planned: starting from the outcomes
of this large data collection on PPBR we will analyze the impact of a
more careful patient selection on the postoperative complication as well
as implant loss rate. A prospective evaluation of the effect of radio-
therapy is planned too. Other limits of this study were that esthetic and
patient‐reported outcomes were not reported and that postoperative
pain scores were available only for a minority of patients so that could
not be included as an outcome measure. This leaves room for further
discussion of results, in particular in a longer follow‐up and a greater
number of irradiated patients so that to drawmore stable conclusions in
this interesting subgroup of patients.
5 | CONCLUSIONS
The iBAG study brings the largest evidence on PPBR, collecting the
experience of 30 hospital centers in a 6‐year period. The audit col-
lected homogeneous data on 1450 procedures carried out by wrap-
ping the implant with a preshaped porcine ADM; data analysis
highlighted lasting results with low complication rates and defined
the risk factors involved in the onset of postoperative complications.
The iBAG multicentre data collection represents a milestone in the
field of breast reconstruction, extensively improving the knowledge
of this procedure. Further prospective studies are expected to
achieve a clearer picture of a patient's satisfaction and the impact of
radiotherapy on the outcomes of prepectoral reconstruction.
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